The immunogenicity of human malignant melanoma is well documented (Topalian et al., 1989) . Nevertheless, melanomas obviously escape immune surveillance (Rosenberg, 1991) . The failure of the immune system to effectively respond to and to reject the tumour indicates mechanisms 'paralysing' tumourspecific responses (Russel, 1990; Hock et al., 1993) . One of the possibilities is the secretion of immunosuppressive factors either by tumour-infiltrating cells and/or by the tumour cells themselves. A candidate for such a factor in humans is interleukin 10 (IL-10), which has been shown to dampen the immune response by down-regulating the secretion of several cytokines by T cells and monocytes (Vieira et al., 1991; De Waal Malefyt et al., 1991a ; Ralph et al., 1992) and by reducing antigen-specific activation of T lymphocytes by diminishing the antigen-presenting capacity of monocytes (De Waal Malefyt et al., 1991b; Tosato & Taga, 1992) .
Therefore, we investigated the expression of IL-10 mRNA in tissue specimens of primary malignant melanomas and melanoma metastases as compared with normal skin using reverse transcriptase polymerase chain reaction (RT-PCR) analysis. This approach has already been shown to be valuable for the evaluation of profiles of cytokine expression in tissues, e.g. in leprosy lesions (Yamamura et al., 1991) . In addition, we screened established human melanoma cell lines as well as normal melanocytes, keratinocytes and fibroblasts, the major cellular constituents of normal skin, for expression of IL-10 mRNA and secretion of IL-10 protein. stimulated lymphokine activated killer (LAK) cells] and a negative control consisting either of reaction mix without cDNA or of sample RNA that had not been reverse transcribed. For comparison of IL-10 mRNA levels in different tissue specimens, cDNAs were first adjusted to equal concentrations of P-actin by competitive PCR as recently described (IJberla et al., 1991) . Briefly, serial 10-fold and subsequently 2-fold dilutions of cDNA were amplified in the presence of a fixed amount of P-actin control fragment, in order to determine exactly the amount of cDNA required to achieve equal '." Macmillan Press Ltd., 1994 band intensities for both fragments. The so-equalised cDNAs were then analysed for IL-10 mRNA content. Specificity of amplification products was verified by restriction analysis with two enzymes indicative for the expected amplified sequence (data not shown). Electrophoresis of 20 jil of PCR reaction or digestion product on 1.5% agarose gel containing ethidium bromide was performed to evaluate amplification and size of the generated fragments in comparison with the KB DNA ladder (Gibco/BRL, Gaithersburg, MD, USA). Primer sequences for ,-actin (positions 103-122 and 642-619) and IL-10 (positions 283-309 and 608-634) were taken from Yamamura et al. (1991) and crossed intron-exon boundaries in genomic DNA.
Materials and methods

Specimens
Assays for IL-1O reactivity Melanoma cells and melanocytes were incubated for 48 h at 1 x 106 cells ml-' and supernatants (SNs) were collected. SNs were assayed for IL-10 activity by an IL-10 enzyme-linked immunosorbent assay (ELISA) kit according to the supplier's recommendations (Cytoscreen, BioSource International, Camarillo, CA, USA). The lower detection limit of the ELISA was 18 pg ml' for human IL-10. In addition, IL-10 activity was tested in the murine D36 mast cell proliferation assay (Schlaak et al., 1993) . Functionally, human IL-10 has been shown to possess the same biological activity as murine IL-10 when tested on murine cell targets (Vieira et al., 1991 To investigate the expression of IL-10 mRNA in small specimens of human primary melanoma and melanoma metastases, we extracted total cellular mRNA from tissue specimens, and reverse transcribed it to cDNA. To provide meaningful comparison between different tissue samples, cDNAs were normalised to P-actin PCR product by competitive amplification of the cDNAs with a P-actin control fragment (see Figure 1) . These standardised cDNA samples were analysed for IL-10 transcripts using IL-10-specific primers. Four out of five primary melanomas expressed IL-10 mRNA, whereas four out of five matched normal skin samples showed no IL-10 transcripts at all, and one skin sample barely expressed IL-10 mRNA (Figure 1 ). In addition, all three melanoma metastases analysed clearly expressed IL-10 mRNA.
Expression of IL-JO mRNA and secretion of IL-JO protein in cell cultures To determine whether melanoma cells themselves express IL-10 mRNA and may be a source of IL-10 mRNA observed in melanoma tissues, we screened 13 human melanoma cell lines for gene expression of IL-10 by RT-PCR analysis as compared with normal melanocytes, keratinocytes and fibroblasts. As illustrated in Figure 2a , 3 out of 13 melanoma cell lines strongly expressed mRNA of IL-10, one showed moderate and three weak expression, whereas six cell lines were negative. In melanocyte cultures from seven different donors, weak but clearly detectable levels of IL-10 mRNA were consistently observed (Figure 2b ), while fibroblasts and keratinocytes (cultures from two different donors) did not express IL-10 mRNA (data not shown). The amounts of cDNA analysed were similar in various samples and also between different cell types, as could be shown by amplification of,-actin mRNA (Figure 2) . We next analysed SNs of these 13 melanoma cell lines and seven melanocyte cultures for IL-10 reactivity. The level of IL-10 mRNA detected in melanoma cell lines by RT-PCR correlated with the amount of IL-10 found in SNs, ranging form 0.57 ng ml-' to 3.40 ng ml-' IL-10 (Table I) (Yamamura et al., 1993) . The present finding, that metastatic lesions which normally show less inflammatory response than primary melanomas (Payan et al., 1970 ) expressed levels of IL-10 mRNA similar to the primary tumours, together with the fact that several melanoma cell lines constitutively secreted IL-10 rather argues for the possibility that IL-10 in melanoma tissue may be produced by the tumour cells themselves. However, to characterise unequivocally IL-10-expressing cells in the melanoma tissues either in situ hybridisation or immunohistochemistry has to be applied in further investigations. Melanocytes, the benign counterparts of melanoma cells, weakly expressed IL-10 mRNA but did not produce detectable IL-10 protein, nor did fibroblasts and keratinocytes. In one out of five normal skin samples examined in the present study, IL-10 mRNA was detected. In support of these results, constitutive expression of IL-10 mRNA has been found occasionally in unstimulated murine skin and reproducibly in hapten-stimulated skin samples (Enk & Katz, 1992) . Accordingly, hapten-stimulated murine keratinocytes expressed IL-10 mRNA and protein. Possibly, appropriate stimulation may lead to IL-10 expression by human keratinocytes as well. Interestingly, selective expresssion of IL-10 mRNA has also been found in ovarian tumours but not in normal ovaries and ovarian tumour cell lines (Pisa et al., 1992) . Moreover, our results are in line with recent published PCR data on the comparison of cytokine profiles in another malignant tumour of the skin, namely basal cell carcinoma, to that of seborrhoeic keratosis, a benign hyperplasia of epidermis (Yamamura et al., 1993) . The authors noted prominent mRNA expression of IL4 and IL-10 in carcinoma specimens, but of IL-2 and interferon gamma in irritated seborrhoeic keratosis. Most recently, the constitutive production of IL-10 mRNA and protein by several human carcinoma cell lines has been reported (Gastl et al., 1993) . IL-10 was produced predominantly by epithelial cancer cell lines such as colon carcinoma, malignant melanoma and renal cell carcinoma. While these studies were restricted to established cell lines we could additionally demonstrate expression of IL-10 in tissues of primary and metastatic melanomas. IL-10 is a pleiotropic cytokine, and there is accumulating evidence from in vitro systems that IL-10 may play an important role not only in the regulation of T cell responses, but also as an anti-inflammatory mediator in vivo (Richter et al., 1993) . It is therefore intriguing to speculate that IL-10 suppresses antitumour immune responses and thereby facilitates tumour growth and development. IL-10 in human tumours could act, for example, by reduction of cell-mediated cytotoxicity and antigen presentation by monocytes (De Waal Malefyt et al., 1991b) , or by down-regulation of tumour necrosis factor oc and/or interferon gamma production, two tumoricidal products of monocytes and T cells (De Waal Malefyt et al., 1991a; Ralph et al., 1992; Tosato & Taga, 1992; Del Prete et al., 1993) .
Most recently, production of IL-10 mRNA and IL-10 protein could be detected in situ in AIDS lymphomas (Emilie et al., 1992) . Expression of IL-10 was associated with the presence of Epstein-Barr virus in lymphomatous cells. Human IL-10 exhibits extensive sequence homology to a previously uncharacterised open reading frame in the Epstein-Barr virus genome, BCRF-I (Vieira et al., 1991) . The protein product of BCRF-1, designated viral IL-10, shares most properties with IL-10, including cytokine synthesisinhibtory activity on T cells (Hsu et al., 1990 ) and suppression of antigen-specific proliferative T-cell response as a result of down-regulation of class II major histocompatibility complex molecules on monocytes (De Waal Malefyt et al., 1991b) . The possibility that messages detected in the PCR analysis of melanoma lesions may result from BCRF-I expression is ruled out, since PCR primers were designed to specifically amplify mRNA of human IL-10 but not mRNA of viral IL-10 (Hsu et al., 1990; Vieira et al., 1991) .
Our present data demonstrate the selective expression of IL-10 mRNA in human melanoma tissue. In addition, produteion of biologically active IL-10 has been found in some melanoma cell lines. There are several reports that melanoma cell lines express mRNAs and also proteins for various cytokines, e.g. IL-1, IL-6, IL-8, IL-10, tumour necrosis factor a and granulocyte colony-stimulating factor (Colombo et al., 1992 , and reviewed therein; Gastl et al., 1993) . These and other cytokines are likely to be involved in the immune response to cancer. At this time it is unclear what the net effects of multiple cytokines are on the outcome of the host response to tumour. For unknown reasons some (about 20%) but not all melanoma patients respond to IL-2 immunotherapy (Rosenberg, 1991) . The presence of IL-10 in melanoma lesions, whatever its source may be, might influence the immune response to this tumour. The role of IL-10 as a possible prognostic marker for successful immunotherapy remains to be investigated.
